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ABSTRACT
Background. Controlled trials have demonstrated the efﬁcacy of antihistamines in the treatment of chronic idio-
pathic urticaria. Second-generation antihistamines are recommended as ﬁrst-line therapy for chronic idiopathic
urticaria. The purpose of this study was to determine the effect of desloratadine, a newer, nonsedating, second-
generation antihistamine, on symptoms of chronic idiopathic urticaria, disease severity, and quality of life (QoL).
Methods. In an open-label, observational, multicenter study, 348 subjects with chronic idiopathic urticaria were
given 5 mg of desloratadine once daily for 2 weeks. Outcome measures included change from baseline at Day 14
using the Aerius Quality of Life Questionnaire (AEQLQ); change from baseline in pruritus score, number and
maximum size of hives, sleep quality, and activity impairment; and subjects’ response to therapy.
Results. Desloratadine signiﬁcantly decreased subjects’ overall condition and symptom scores from baseline to Day
14 (2.19  [SD] 0.66 and 1.14  0.89, respectively; P < 0.0001). Desloratadine treatment signiﬁcantly improved all
10 AEQLQ domain scores from baseline to Day 7 and Day 14 (P < 0.0001). Sleep disturbance scores decreased 40%
from baseline to Day 7 (1.42  1.03 to 0.85  0.89, respectively), and interference with daily outdoor activity scores
showed a 41% decrease from baseline to Day 7 (1.11  0.98 to 0.66  0.90) (P < 0.0001 for both). There were
signiﬁcant reductions in itching, size of hives, and hive score at both Days 7 and 14. Treatment resulted in moderate,
marked, or complete relief of symptoms in 76.2% of subjects. Desloratadine was well tolerated, with no adverse
events reported.
Conclusion. In an open-label, observational study, desloratadine 5 mg once daily signiﬁcantly decreased symptoms
of chronic idiopathic urticaria and improved subject QoL.
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Introduction
C
hronic urticaria, or urticaria that lasts longer
than 6 weeks, is a common and frustra-
ting condition [1]. Chronic idiopathic urticaria, or
chronic urticaria of undeﬁned etiology, occurs in
about 70% of patients diagnosed with chronic urti-
caria and affects about 0.1% to 3% of the general
population [2–4]. Because classiﬁcation of urticaria
iscomplexandincludesaspectrumofclinicalmani-
festations and subtypes, recent guidelines do not
distinguish between chronic urticaria and chronic
idiopathic urticaria. Given that the differential dia-
gnosis is difﬁcult and treatment approaches do not
differ greatly, chronic urticaria may become the
preferred term in the future [5,6]. The idiopathic
nature of chronic idiopathic urticaria has been cur-
tailed by the growing appreciation of the role of
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in the pathophysiology of the disease [7–11].
The effect of chronic idiopathic urticaria on the
patient depends on the duration and severity of the
condition [1]. Up to 20% of patients with chronic
idiopathic urticaria have symptoms for 10 to 20
years [12,13]. Patients can be greatly affected by
the recurrent itch and physically unappealing
appearance of the lesions associated with chronic
idiopathic urticaria [1,14]. Other factors, such as
anxiety induced by the continual relapses, uncer-
tainty of the cause, and negative effects on social
life, may also contribute to a decline in quality of
life (QoL) [15]. The profound effect of the physi-
cal symptoms of chronic idiopathic urticaria on
patients’ emotions and daily functioning is partly
due to sleep disruption [1,14,16–18]. This can lead
to fatigue, loss of energy, and physical and mental
disturbance [14]. Despite the fact that chronic
idiopathic urticaria interferes with patients’ sense
of well-being and QoL [16,19], physicians gener-
ally underestimate the condition’s effect on their
patients’ lives [15].
Controlled trials have demonstrated the efﬁcacy
of antihistamines in the treatment of chronic
idiopathic urticaria [20]. Second-generation anti-
histamines are the recommended ﬁrst-line therapy
for chronic idiopathic urticaria [6]. Desloratadine,
a newer, nonsedating, second-generation antihis-
tamine, is effective, safe, and provides rapid onset
of action and long duration of symptom relief
while improving QoL [1,21,22].
This ofﬁce-based trial was designed to study
desloratadine therapy for chronic idiopathic urti-
caria in the real-world setting of everyday clinical
practice (and the type of patient population nor-
mallyseeninsuchapractice).Itemployedachronic
idiopathicurticaria-speciﬁcinstrument,theAerius
1
QualityofLifeQuestionnaire(AEQLQ)(Table 1),
and patient diaries to assess the effect of deslorata-
dine5 mgoncedailyonchronicidiopathicurticaria
symptoms, disease severity, daily activities, and
patient QoL.
Methods
Study Design
This open-label, 2-week study evaluated the im-
pact of desloratadine on QoL, symptom relief,
and improvement in disease severity in a non-
randomized setting. Physicians from 157 medical
centers across Canada could recruit up to 5 sub-
jects each. Subjects were required to complete 2
visits: one at baseline (Day 1) and another at
Day 14. Subjects evaluated their QoL at baseline,
1Desloratadine is marketed as Aerius® (Schering-Plough,
Kenilworth, NJ, USA) in Europe and Canada.
Table 1 Aerius Quality of Life Questionnaire (AEQLQ)
The aim of this questionnaire is to measure how your skin problem
has affected your life OVER THE PAST WEEK. Please tick ✓ one
box for each problem.
OVER THE PAST WEEK . . .
Symptoms
1. Have you been bothered by symptoms, such as itchiness, pain,
soreness, or a stinging sensation?
Very much __3
A lot __2
A little __1
Not at all __0
2. Have your skin symptoms interfered with the quality or length of
your sleep?
Very much __3
A lot __2
A little __1
Not at all __0
Interference with usual activities
3. Have your skin symptoms interfered with your outdoor activities?
Very much __3
A lot __2
A little __1
Not at all __0
4. Have your skin problems affected your ability to participate in
sports or other physical activities?
Very much __3
A lot __2
A little __1
Not at all __0
5. Have your skin problems affected your ability to participate in
leisure or other social activities?
Very much __3
A lot __2
A little __1
Not at all __0
6. Have your skin problems interfered with your ability to work or
study?
Very much __3
A lot __2
A little __1
Not at all __0
Social aspects
7. Are you embarrassed or self-conscious about your skin?
Very much __3
A lot __2
A little __1
Not at all __0
8. Have your skin problems created problems with your partner,
close friends, or relatives?
Very much __3
A lot __2
A little __1
Not at all __0
9. Have your skin problems interfered with your ability to engage in
or enjoy sexual activities?
Very much __3
A lot __2
A little __1
Not at all __0
10. Have your skin problems inﬂuenced how you dress?
Very much __3
A lot __2
A little __1
Not at all __0
Please check you have answered EVERY question. Thank you.
64 Kim and Lynde
Arch Drug Info 2008;1:63–69Day 7, and Day 14 using the AEQLQ. Diaries
were provided, and subjects were instructed to
make daily entries on time of medication dosing,
interference with sleep (morning only), and in-
terference with daily outdoor activities (evening
only), and to assess twice daily severity of pruri-
tus, number of hives, and size of the largest hive.
Subjects who completed the questionnaires
and the diary received a $25 gift certiﬁcate for
their participation. Physicians received $100 per
subject enrolled. Medication was supplied free of
charge.
This study was conducted under the auspices of
a centralized institutional review board, in accor-
dance with the principles of the 1974 Declaration
of Helsinki and subsequent amendments. All sub-
jects provided written informed consent.
Subjects andTreatment
Subjects were eligible to enroll if they were 18
years of age; were diagnosed with chronic idio-
pathic urticaria; and had a hive score of 1, a
pruritus score of 2, and an overall condition
score of 2 (see below for scoring system). Inclu-
sion criteria included a 6-week history of chronic
idiopathic urticaria and a current ﬂare of at least
3-weeks’ duration (hives present at least 3 days per
week). Subjects were excluded if they were preg-
nant or breastfeeding; had documented drug or
food allergies; had other known etiologic factors
contributing to their urticaria; or had a history
of hypersensitivity to desloratadine or any of its
excipients. Subjects were instructed to take one
5-mg desloratadine tablet daily at approximately
the same time in the morning for 14 days. Con-
comitant medications for chronic idiopathic
urticaria, including topical creams and other anti-
histamines, were reviewed and recorded by the
physician at baseline and ﬁnal visit. The most
common concomitant medications recorded at
baseline were cetirizine (taken by 24.1% of sub-
jects), diphenhydramine (11.5%), and hydroxyzine
HCl (11.2%); the most common concomitant
medications recorded at ﬁnal visit (other than
desloratadine) were cetirizine (15.1% of subjects),
hydroxyzine HCl (14.3%), and diphenhydramine
(7.1%). Subjects could adjust concomitant medi-
cation dosing as required.
Efﬁcacy and Safety Assessments
Symptom scores were rated jointly by physi-
cians and subjects at baseline and through review
of subjects’ daily diaries at ﬁnal visit, reﬂecting
real-world clinical practice in which patients and
physicians estimate disease severity in concert.
Evaluationsincludedseverityofitching,hivescore,
and overall condition. Quality of life was assessed
using the AEQLQ, which consists of 10 equally
weighted questions (severity of symptoms, inter-
ference with sleep, interference with outdoor acti-
vities, ability to participate in sports/physical
activities, ability to participate in leisure/social
activities, ability to work or study, feelings of
self-consciousness, problems with partner/close
friends/relatives, sexual dysfunction, and inﬂuence
on dress). This questionnaire is based on the Der-
matology Life Quality Index (DLQI), a validated
measure of QoL in subjects with skin diseases [23];
the AEQLQ substitutes a question on sleep for the
DLQI’s question on disease treatment. Subjects
completed the AEQLQ at baseline, Day 7, and
Day 14.
Symptom relief and improvement in disease
severity were evaluated using subjects’ daily dia-
ries. Subjects recorded the time medication was
taken daily; a self-assessment evaluation (pruritus,
number of hives, size of largest hive) twice daily;
interference with sleep once daily in the morning;
and interference with daily activities once daily in
the evening. Pruritus was rated on a scale of 0 to 3,
with 0 being not present and 3 being the most
severe. Hives were rated on a scale of 0 to 4, with
0 representing no hives and 4 representing 20
hives. The size of the largest hive was rated on a
scale of 0 to 3, with 0 representing no hives and 3
representing hives >2.5 cm. Interference with
sleep or daily activities was rated on a scale of 0 to
3, with 0 representing none and 3 representing
severe disturbances.
At the ﬁnal visit, physicians and subjects jointly
assessed response to treatment according to the
following classiﬁcations: complete relief, marked
relief, moderate relief, slight relief, or treatment
failure. Physicians were instructed to report all
adverse events (AEs). Adverse events were moni-
tored by the treating physician and followed to
satisfactory resolution or stabilization. Adverse
events were deﬁned as any unfavorable and unin-
tended sign, symptom, or disease associated with
the use of a medicinal product, whether it was
considered related to the medicinal product;
occurring in the course of the use of a drug,
biological product, or device; associated with, or
observed in conjunction with, product overdose,
whether accidental or intentional; associated with,
or observed in conjunction with, product abuse;
and/or associated with, or observed in conjunction
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sidered to be any AE occurring at any dose that
resulted in death, a life-threatening adverse drug
experience, inpatient hospitalization, a persistent
or signiﬁcant disability/incapacity, or a congenital
anomaly or birth defect.
Statistical Analysis
In this single-cohort, repeated-measure, observa-
tional study, self-reported nominal/ordinal depen-
dent variables were treated as continuous variables;
the different severity categories (from none to
severe) were assigned and parametric statistical
methods were performed on the main score. A
repeated-measure analysis of variance (ANOVA)
was used for the primary outcome variables
(symptom evaluation, global response, and QoL).
These test whether or not the observed change
frombaselinetoDay14islikelytobeduetochance
(i.e.,arandomeffect).Posthoc,pair-wisecompari-
sons were also performed for analysis time points.
To evaluate the impact of concomitant medication
on outcome parameters, a mixed-model ANOVA
analysiswasused.Noadjustmentformultiplecom-
parisons was performed.
Results
Subject (N = 348) baseline characteristics are out-
lined in Table 2. In 327 subjects who completed
the study, desloratadine signiﬁcantly decreased
itching scores from baseline to Day 14 (1.98 
0.87 vs. 0.89  0.90; P < 0.0001), as evaluated by
physicians and subjects by discussion at baseline
and by reviewing diary entries at Day 14 (Figure 1;
Table 3). According to subjects’ daily diary entries,
desloratadine treatment resulted in signiﬁcant
reductions in itching at Days 7 and 14 from base-
line (1.34  1.01 at baseline vs. 0.73  0.92 at Day
7 and 0.90  0.96 at Day 14; P < 0.0001) (Table 4).
There was an additional signiﬁcant reduction in
itching from Day 7 to Day 14 (P = 0.0101).
Desloratadine treatment also resulted in sig-
niﬁcant reductions in the size of hives and hive
scores at Days 7 and 14 from baseline (P < 0.0001).
Improvements were observed early during treat-
ment and continued to Day 14.
Subject diary entries showed that interference
with sleep had signiﬁcant improvements by Day 7
and Day 14 (P < 0.0001). Interference with daily
outdoor activities also signiﬁcantly improved by
Day 7 and Day 14 (P < 0.0001).
Desloratadine signiﬁcantly decreased subjects’
overall condition (combined score for itching and
number of hives) from baseline to Day 14 (2.19 
0.66vs.1.14  0.89;P < 0.0001).Subjectsreported
itching and number of hives as twice-daily diary
entries. Physicians and subjects jointly determined
itchingscorebydiscussionatbaselineandbyreview
of subject diary entries at Day 14. Desloratadine
treatment also signiﬁcantly decreased scores for all
10 AEQLQ measures from baseline to Day 7 and
to Day 14 (P < 0.0001). Incremental signiﬁcant
decreases were observed from Day 7 to Day 14 for
all domains on the AEQLQ except “created prob-
lems with partner.” Sleep interference scores were
reduced by 40% from baseline to Day 7 (1.42 
1.03vs.0.85  0.89)and52%frombaselinetoDay
14 (1.42  1.03 vs. 0.68  0.83). Interference with
work/study scores showed a 41% decrease from
baselinetoDay7anda50%decreasefrombaseline
to Day 14. Desloratadine treatment resulted in
moderate (21.7%), marked (30.3%), or complete
(24.2%) relief of symptoms.
In this study, desloratadine was well tolerated,
with no AEs reported. A total of 21 subjects were
lost to follow-up.
Table 2 Study population: subject characteristics
(N = 348)
Mean  SD
Age (years) 44.2  14.9
Number of months subject had suffered from
chronic idiopathic urticaria
35.2  71.5
Duration of current ﬂare (months) 4.4  5.6
n%
Female 244 70.1%
Subjects taking NO concomitant medications
at baseline
70 20.1%
Subjects taking NO concomitant antihistamine
at baseline
122 35.1
Figure 1 Combined physician and subject itching score
(0–3 scale) at baseline and ﬁnal visit.
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Treatmentforurticariabeginswiththeelimination
ofanyknowncausativeorexacerbatingfactors(i.e.,
cold, light, or pressure); therefore, taking a com-
prehensive patient history is paramount. However,
as the causes of nonphysical or autoimmune-based
chronic urticaria are by deﬁnition unknown, treat-
ment typically focuses on symptom relief.
The most common approach to managing
chronic urticaria is to prevent the release of his-
tamine or to block its effects at receptor sites
on nerves and endothelial cells. Therefore, H1
antihistamines are the cornerstone of urticaria
treatment. First-generation antihistamines (e.g.,
brompheniramine, diphenhydramine, and keto-
tifen) are effective, but they are also associated
with AEs caused by their lack of selectivity for the
H1 receptor (e.g., antimuscarinic effects, appetite
stimulation, weight gain, gastrointestinal effects),
as well as their binding to cerebral H1 receptors,
which causes central nervous system effects, such
as somnolence and cognitive impairment. Newer,
second-generation agents, such as desloratadine,
are therefore generally preferred as ﬁrst-line ther-
apy for chronic urticaria due to their proven efﬁ-
cacy and favorable safety proﬁles [24].
Although chronic urticaria occasionally resolves
spontaneously, symptoms can potentially last for
many years. The prolonged duration of the disease
can have a profoundly negative impact on a
patient’s sense of well-being. Long-lasting, safe,
and effective second-generation antihistamines
have been shown to substantially improve patient
QoL and, therefore, remain the ﬁrst choice for
chronic urticaria therapy.
Table 3 Main efficacy results
Evaluation (range of score) Baseline Day 7 Day 14 P value
Symptom
Itching (0–3) 1.98  0.87 — 0.89  0.90 <0.0001
Hive score (0–4) 2.12  1.44 — 1.02  1.31 <0.0001
Overall condition (0–3) 2.19  0.66 — 1.14  0.89 <0.0001
Quality of life (0–3)
Bothered by CIU symptoms 2.08  0.83 1.36  0.87 1.17  0.91 <0.0001
CIU interfered with sleep 1.42  1.03 0.85  0.89 0.68  0.83 <0.0001
CIU interfered with outdoor activity 1.11  0.98 0.66  0.90 0.56  0.87 <0.0001
CIU interfered with sports 0.90  0.97 0.59  0.88 0.48  0.86 <0.0001
CIU interfered with leisure/social 1.05  1.01 0.62  0.88 0.49  0.82 <0.0001
CIU interfered with work/study 1.11  0.96 0.65  0.88 0.56  0.82 <0.0001
Embarrassed, self–conscious about skin 1.55  1.05 1.03  1.01 0.88  0.97 <0.0001
CIU created problems with partner 0.55  0.82 0.35  0.67 0.30  0.63 <0.0001
CIU interfered with sexual activities 0.64  0.95 0.47  0.87 0.35  0.75 <0.0001
CIU inﬂuenced dressing 1.33  1.09 0.96  1.04 0.80  0.99 <0.0001
Global response to therapy (0–5) — — 2.59  1.33 —
Table 4 Subject diary ratings
Symptom (range of score) Baseline Day 7 Day 14
Itching (0–3)*
Day 1.34  1.01 0.73  0.92 0.90  0.96
Night 1.58  0.98 0.84  0.99 0.96  1.01
Size of hives (0–3)
†
Day 1.28  1.09 0.83  0.94 0.97  1.03
Night 1.53  1.07 1.07  1.09 0.93  1.02
Number of hives (0–4)
‡
Day 1.81  1.49 1.13  1.40 1.38  1.47
Night 2.13  1.51 1.21  1.43 1.42  1.51
Interference with sleep (0–3)
§
Morning 0.99  1.10 0.57  0.90 0.49  0.84
Interference with daily activities (0–3)
¶
Evening 0.93  0.88 0.49  0.82 0.62  0.90
*P < 0.0001 baseline vs. Day 7 and Day 14; P = 0.0101 Day 7 vs. Day 14. (AM); P = 0.0701 Day 7 vs. Day 14 (PM).
†P < 0.0001 baseline vs. Day 7 and Day 14; P = 0.0329 Day 7 vs. Day 14; P = 0.0181 Day 7 vs. Day 14 (PM).
‡P < 0.0001 baseline vs. Day 7 and Day 14; P = 0.0043 Day 7 vs. Day 14; P = 0.0102 Day 7 vs. Day 14 (PM).
§P < 0.0001 baseline vs. Day 7 and Day 14; P = 0.2302 Day 7 vs. Day 14.
¶P < 0.0001 baseline vs. Day 7 and Day 14; P = 0.0096 Day 7 vs. Day 14.
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dine resulted in rapid improvements across all
measured QoL domains. Signiﬁcant improve-
ments were observed by Day 7 in all 10 measured
AEQLQ domains, and continued improvement
was seen on Day 14. Desloratadine reduced
itching during the night, interference with sleep,
and interference with daily activities from Day 1
through the end of the 14-day study period as
assessed by subjects in their daily diaries.
Limitations
The QoL tool used in this study, the AEQLQ, is
based on and derived from the validated QoL
instrument DLQI, which has been widely used in
dermatology across a variety of disease states.
Studies of desloratadine that are similar to the one
outlined in this paper have used the DLQI and
have been published in peer-reviewed literature.
We have veriﬁed that the AEQLQ, although
derived from a validated tool, has neither been
validated nor been cited previously. There were
several limitations in the study design. The study
used a single agent in an open-label design and
was not placebo controlled; however, an open-
label design in a patient population normally seen
in clinical practice more closely approximates a
physician’s everyday experience. In addition, mul-
tiple statistical comparisons were made without
adjustment, and no data were available for the 21
subjects who were lost to follow up.
Conclusion
In this open-label, multicenter, uncontrolled ob-
servational study in 348 subjects with chronic
idiopathic urticaria, desloratadine 5 mg once daily
signiﬁcantly improved QoL, pruritus, hive size
and number, and overall condition. Improvements
were noted at Day 7 and Day 14.
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